- Home
- CBAT vs HLVX Comparison
CBAT vs HLVX Comparison
Compare CBAT & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAT
- HLVX
- Stock Information
- Founded
- CBAT 1999
- HLVX 2020
- Country
- CBAT China
- HLVX United States
- Employees
- CBAT N/A
- HLVX N/A
- Industry
- CBAT Industrial Machinery/Components
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- CBAT Miscellaneous
- HLVX Health Care
- Exchange
- CBAT Nasdaq
- HLVX Nasdaq
- Market Cap
- CBAT 71.6M
- HLVX 83.7M
- IPO Year
- CBAT N/A
- HLVX 2022
- Fundamental
- Price
- CBAT $0.73
- HLVX $1.45
- Analyst Decision
- CBAT
- HLVX Hold
- Analyst Count
- CBAT 0
- HLVX 5
- Target Price
- CBAT N/A
- HLVX $2.33
- AVG Volume (30 Days)
- CBAT 158.7K
- HLVX 157.5K
- Earning Date
- CBAT 03-17-2025
- HLVX 03-28-2025
- Dividend Yield
- CBAT N/A
- HLVX N/A
- EPS Growth
- CBAT N/A
- HLVX N/A
- EPS
- CBAT 0.13
- HLVX N/A
- Revenue
- CBAT $176,614,609.00
- HLVX N/A
- Revenue This Year
- CBAT $28.79
- HLVX N/A
- Revenue Next Year
- CBAT $36.77
- HLVX N/A
- P/E Ratio
- CBAT $5.67
- HLVX N/A
- Revenue Growth
- CBAT N/A
- HLVX N/A
- 52 Week Low
- CBAT $0.71
- HLVX $1.37
- 52 Week High
- CBAT $2.08
- HLVX $16.31
- Technical
- Relative Strength Index (RSI)
- CBAT 29.57
- HLVX 30.91
- Support Level
- CBAT $0.71
- HLVX $1.37
- Resistance Level
- CBAT $0.90
- HLVX $1.54
- Average True Range (ATR)
- CBAT 0.05
- HLVX 0.08
- MACD
- CBAT -0.01
- HLVX -0.02
- Stochastic Oscillator
- CBAT 8.95
- HLVX 19.28
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.